E-raamat: Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes

Dr. Vijay Mishra, PhD, is a Professor at the School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab), India. He earned his doctoral degree in Pharmaceutical Sciences from Dr. H.S. Gour Central University, Sagar (MP), India. He has 15+ years of academic and research experience. Dr. Mishra has authored more than 160 research and review articles in various peer-reviewed international journals of high repute, 25 book chapters, 9 books, 10 Indian patents (filed and published), 1 Australian and 1 Indian patent (granted) and 5 Indian Copyrights (Granted). He has an h-index 43 and 6400+ citations to his credit. He has been a recipient of several internationally acclaimed fellowships and awards including Graduate Research Fellowship (AICTE, New Delhi), UGC-BSR Senior Research Fellowship (UGC, New Delhi) and International Travel Award/Grant (DBT, New Delhi). He is a life member of Indian Science Congress Association, Kolkata, India. He serves as an Editorial Board Member of various peer-reviewed journals. Dr. Mishra has been selected as the Worlds Top 2% scientists in 2021, 2022, 2023, and 2024 as per Stanford University, USA report. His current research interests encompass nanomedicine, cancer, phytotherapeutics, dendrimers, carbon nanotubes, and novel drug delivery systems. Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as USERN Laureate award”, most prestigious SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.

Dr. Mohd Cairul Iqbal Mohd Amin is a Professor of Pharmaceutics in the Faculty of Pharmacy, Universiti Kebangsaan Malaysia (UKM) in Kuala Lumpur, Malaysia. He is the youngest professor appointed in the faculty and the only expert in the area of pharmaceutics in UKM. He earned his BSc (Hons) in Pharmacy in 1996 and PhD in 2001 both from the University of Manchester, United Kingdom. He is currently the Head of Drug Delivery and Novel Targeting Research Group in UKM. He also serves as panel expert in nanocellulose for drug delivery for the National Nanotechnology Centre, Ministry of Science, Technology and Innovation, Malaysia. His current research interests encompass responsive-hydrogel biomaterials for oral protein and peptide delivery, cell delivery in tissue engineering and nano drug delivery systems in particular polymeric micellar conjugates for cancer research. Dr. Amin has authored more than 60 publications in high impact factor journals, a number of book chapters, has five patents issued/pending and has routinely consulted in the area of drug delivery and pharmaceutical technology. He has wide expertise in biomaterials, nanomedicine, polymer chemistry, micro- and nanotargeting delivery systems as well as oral and transdermal formulations and delivery systems. Dr. Iyer is the Director of Use-inspired Biomaterials and Integrated Nano Delivery (U-BiND) Systems Laboratory and an Associate Professor with Tenure in the Department of Pharmaceutical Sciences at Wayne State University in Detroit, Michigan, USA. He also serves as a Scientific Member of the Molecular Imaging Program (MIP) at the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, USA. Dr. Iyer received his PhD in 2008, in Polymer Engineering, under the mentorship of world-renowned scientist and 2016 Nobel Prize in Chemistry Nominee, Prof. Hiroshi Maeda at Sojo University in Kumamoto, Japan. Dr. Iyer was the recipient of the Controlled Release Societys (CRS) T. Nagai Research Achievement Award in 2012. Dr. Iyer completed his postdoctoral training in Cancer Radiology at the University of California, San Francisco (UCSF) in California, USA. In 2018 Dr. Iyer received an Early Career Investigator Award from the US Department of Defense (DoD). Dr. Iyer has authored more than 100 publications in peer reviewed International Journals (H-index:45), and books of high repute. He has more than 200 scientific presentations and invited talks at International Conferences and Workshops. He has five patents issued/pending. His areas of research are broadly focused on designing use-inspired bio- and nano-medical technologies aimed towards clinical translation using biocompatible delivery systems that have enhanced disease targeting with reduced toxicity burden to patients. He has wide expertise in biomaterials and nanomedicine, polymer chemistry and formulation development, drug and gene delivery systems, molecular and functional imaging, micro and nanoparticles for treating diseases such as infection,cancerand age-related dementia. His laboratory is funded by agencies such as National Institutes of Health and the US Department of Defense.